Achieve Life Sciences (NASDAQ:ACHV) Issues Earnings Results

Achieve Life Sciences (NASDAQ:ACHV) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.11, FiscalAI reports.

Here are the key takeaways from Achieve Life Sciences’ conference call:

• Achieve said its recent $180 million private placement, with up to $174 million more from milestone warrants, gives the company a strong capital base to pursue approval and launch plans.
• The company expects an FDA complete response letter tied to issues at a prior third-party manufacturer and plans to resubmit the NDA in Q4 2026 with Adare Pharma Solutions as the primary U.S. commercial supply partner.
• Management highlighted encouraging clinical and mechanistic data for cytisinicline, including selective receptor activity that may help explain its low nausea rates and strong efficacy in hard-to-treat patients who previously used varenicline or bupropion.
• Achieve is moving ahead with an independent commercial launch strategy and has added experienced leaders from Verona Pharma, including a new commercial SVP and sales leadership for the field force.
• The company reiterated plans to advance its vaping program, saying it hopes to initiate the ORCA-V2 phase III trial this year while continuing to work with FDA on timelines and trial design.

Achieve Life Sciences Price Performance

Shares of ACHV stock traded down $0.13 during mid-day trading on Thursday, reaching $5.83. The company’s stock had a trading volume of 468,099 shares, compared to its average volume of 977,509. The firm’s 50-day moving average is $4.03 and its two-hundred day moving average is $4.46. The company has a market cap of $310.38 million, a P/E ratio of -5.20 and a beta of 2.25. Achieve Life Sciences has a 1-year low of $2.00 and a 1-year high of $6.15. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.39 and a current ratio of 4.39.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Franklin Resources Inc. boosted its holdings in Achieve Life Sciences by 18,747.4% during the fourth quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company’s stock valued at $21,715,000 after purchasing an additional 4,346,011 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Achieve Life Sciences in the 2nd quarter worth approximately $2,652,000. Millennium Management LLC raised its holdings in shares of Achieve Life Sciences by 472.3% in the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock worth $6,755,000 after buying an additional 1,121,614 shares in the last quarter. Pathstone Holdings LLC bought a new position in shares of Achieve Life Sciences during the 3rd quarter worth approximately $1,581,000. Finally, KVP Capital Advisors LP bought a new position in shares of Achieve Life Sciences during the 4th quarter worth approximately $2,298,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Key Stories Impacting Achieve Life Sciences

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright lifted its FY2026, FY2027, Q2 2026, Q3 2026, and Q4 2026 earnings estimates for Achieve Life Sciences, signaling improved near-term expectations for the company’s financial performance. HC Wainwright earnings estimate revisions
• Positive Sentiment: Despite some changes to out-year forecasts, the analyst maintained a Buy rating and a $12.00 price target, which is well above the stock’s recent trading range and suggests meaningful upside if execution improves. HC Wainwright rating and price target
• Neutral Sentiment: HC Wainwright also trimmed its FY2028, FY2029, and FY2030 EPS forecasts, indicating that while the near-term outlook improved, the longer-term path to profitability remains uncertain. Long-term estimate revisions
• Neutral Sentiment: Recent earnings-call coverage highlighted strategic financing and the company’s regulatory path for cytisinicline, but the article title suggests investors are still weighing the risk of a possible complete response letter and a later NDA resubmission. Seeking Alpha article on cytisinicline and NDA resubmission
• Negative Sentiment: That regulatory uncertainty could cap gains, since Achieve Life Sciences remains a pre-profit biopharmaceutical company and the stock can remain volatile on any delay or setback in its clinical or FDA timeline. Earnings call highlights article

Wall Street Analyst Weigh In

Several equities analysts recently commented on ACHV shares. Weiss Ratings cut shares of Achieve Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. Canaccord Genuity Group set a $13.00 target price on shares of Achieve Life Sciences and gave the company a “buy” rating in a research note on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday, April 16th. Finally, Wall Street Zen upgraded Achieve Life Sciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $14.67.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.